Evidence map›Paper›PMID 41245356›Full record

ArticleContemporary clinical trials communications2025

Time-restricted eating in Alzheimer's disease: TREAD pilot trial design.

Susan B Racette, Jordan A Gunning, Danielle E Eagan, Isabella Zaniletti, Tracy L Smith, Candice J DeCuna, Yehansa S Hettiwatte, Migbare T Demeke, Nevine A Khan, Emily L Aliskevich and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Susan B RacetteCollege of Health Solutions, Arizona State University, Phoenix, AZ, USA.
Jordan A GunningCollege of Health Solutions, Arizona State University, Phoenix, AZ, USA.
Danielle E EaganDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Isabella ZanilettiIZ Statistics LLC, Tampa, FL, USA.
Tracy L SmithDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Candice J DeCunaCollege of Health Solutions, Arizona State University, Phoenix, AZ, USA.
Yehansa S HettiwatteCollege of Health Solutions, Arizona State University, Phoenix, AZ, USA.
Migbare T DemekeDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Nevine A KhanDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Emily L AliskevichDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Janina Krell-RoeschInstitute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.
Yonas E GedaDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.

Funding

The Inorganic Nitrate and eXercise performance in Heart Failure (iNIX-HF): - a phase II clinical trialR33HL155858 · NHLBI · WASHINGTON UNIVERSITY · PI ANDREW R COGGAN, LINDA Ruth PETERSON · 2023 to 2026
$2.9M
NHLBI NIH HHS R33 HL155858
6 · The paper itself

Abstract

Background and objective: Time-restricted eating (TRE) may slow neurodegeneration and cognitive decline by stimulating metabolic processes that are neuroprotective. The primary aim of the TRE in Alzheimer's Disease (TREAD) pilot trial is to evaluate the feasibility of implementing a TRE intervention among individuals with mild cognitive impairment (MCI) and to obtain preliminary data on cognitive domains and blood biomarkers that are responsive to TRE. Methods: TREAD is an intervention trial for 30 adults aged 55-89 years with MCI. A pre/post design is used, with neuropsychological assessments, surveys, and blood biomarkers of cardiometabolic health and AD obtained before and after the intervention. The TRE intervention involves 16 h of continuous fasting and an 8 h eating window on 5 or more days per week for 12 weeks. Feasibility measures include participant enrollment, retention, adherence, acceptability of the intervention, and safety. Cognitive measures include executive function, working memory, processing speed, auditory attention, auditory verbal learning, visuospatial memory, category fluency, and phonemic fluency. Summary: TREAD is exploring an innovative approach to address cognitive decline and will provide critical preliminary data to inform and power a larger, longer-term, randomized controlled trial of TRE on cognitive trajectory among adults with cognitive impairment.

Indexed as

Alzheimer's diseaseMild cognitive impairmentTime-restricted eating

Identifiers

PMID41245356
PMCPMC12612997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.